Publications
29
Citations
532
Est. group size
~4
Recurring co-author estimate
Active years
15
Publishing since 2012
Shabber Mohammed works in medicinal chemistry, designing and synthesizing small-molecule compounds aimed at treating diseases such as tuberculosis, prostate cancer, breast cancer, and inflammatory conditions. This work involves creating new chemical compounds (organic synthesis), testing them for biological activity, and optimizing their drug-like properties such as how well they are absorbed and how selectively they act on their intended targets.
Publication output was low and sporadic in the earlier part of the decade but increased sharply in 2024 and 2025, suggesting a recent growth in research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Netupitant Exhibits Potent Activity on <i>Mycobacterium tuberculosis</i> Persisters
ACS Infectious Diseases · 2025
- Discovery of 2-(4-Ureido-piperidin-1-yl)-4-morpholinothieno [3,2-D] Pyrimidines as Orally Bioavailable Phosphoinositide-3-Kinase Inhibitors with <i>In Vitro</i> and <i>In Vivo</i> Antitumor Efficacy in Triple-Negative Breast Cancer
Journal of Medicinal Chemistry · 2025
- LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy
Cancer Research · 2024
- Netupitant Exhibits Potent Activity on <i>Mycobacterium tuberculosis</i> Persisters
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Abstract 4479: Design, synthesis, and evaluation of amino acid conjugated niclosamide prodrugs as a PepT1 substrate
Cancer Research · 2024
- Prenatal Diagnosis of c.437–1G>A Mutation in the MAN2B1 Gene in a Family With Alpha-Mannosidosis: Unraveling Clinical Presentation and Treatment Outcomes in a Novel Prenatal Case
Cureus · 2024
- Supplementary Information from LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy
2024
- Data from LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy
2024
- Second-Generation Prostaglandin Receptor EP2 Antagonist, TG8-260, with High Potency, Selectivity, Oral Bioavailability, and Anti-Inflammatory Properties
ACS Pharmacology & Translational Science · 2022
- Aryl Methyl Ketones: Versatile Synthons in the Synthesis of Heterocyclic Compounds
SynOpen · 2022
- Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models
Journal of Medicinal Chemistry · 2020
- Discovery of Quinazolin-4(3<i>H</i>)-ones as NLRP3 Inflammasome Inhibitors: Computational Design, Metal-Free Synthesis, and in Vitro Biological Evaluation
The Journal of Organic Chemistry · 2019
- Journal of Medicinal Chemistry×3
- Cancer Research×3
- bioRxiv (Cold Spring Harbor Laboratory)×2
- Cell Reports Medicine×1
- The Journal of Organic Chemistry×1
- Siavash Shahbazi Nia
Chemistry · Purdue University West Lafayette
- Casey J. Krusemark
Chemistry · Purdue University West Lafayette
- Geoffrey M. Williams
Chemistry · Purdue University West Lafayette
- Brennan A. Murphy
Chemistry · Indiana University
- Emma K. Grant
Chemistry · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile